Gan & Lee Pharmaceuticals (SHA:603087) obtained drug registration from El Salvador's health regulator for its insulin glargine injection in a pre-filled pen format.
The product, marketed as Vitaglar, treats diabetes in adults, adolescents and children, according to a Shanghai bourse filing on Tuesday.
Shares of the pharmaceutical company slipped 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments